New drug duo tested in fight against tough cancers
NCT ID NCT03049618
Summary
This study tested whether combining an experimental drug (sEphB4-HSA) with an approved immunotherapy (pembrolizumab) could help control advanced lung or head/neck cancers that had worsened after standard chemotherapy. It involved 42 patients who received both drugs by IV infusion. The main goal was to see how many patients' tumors shrank from this combination treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HEAD AND NECK CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.